BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1559 related articles for article (PubMed ID: 30395986)

  • 1. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
    Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
    J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Huang YS; Chen PY; Chou PC; Wang JT
    Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 16. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
    Castanheira M; Huband MD; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
    Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ito A; Sato T; Ota M; Takemura M; Nishikawa T; Toba S; Kohira N; Miyagawa S; Ishibashi N; Matsumoto S; Nakamura R; Tsuji M; Yamano Y
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.